TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38955437

Group type: EXPERIMENTAL
Intervention: Elevated supine position with back support
Number of subjects: 104

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 104
Study: 38955554

Group type: EXPERIMENTAL
Intervention: High Troponin I (TnI > 6 ng/L)
Number of subjects: 1615

Group type: EXPERIMENTAL
Intervention: High C-reactive protein (CRP > 2 mg/L)
Number of subjects: 1615
Study: 38955577

Group type: EXPERIMENTAL
Intervention: Atezolizumab (n = 37)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 104
Study: 38955669

Group type: EXPERIMENTAL
Intervention: Referral to local SSSs, brief advice, and e-cigarette starter kit (n=505)
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Signposting to SSSs (contact details provided) (n=502)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Referral to SSSs (n=505)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Interviews with 24 intervention participants
Number of subjects: 1007
Study: 38955811

Group type: EXPERIMENTAL
Intervention: High occupational physical activity (OPA) under high work-related stress
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Work-time moderate and vigorous physical activity
Number of subjects: 19
Study: 38955921

Group type: EXPERIMENTAL
Intervention: GAP composite endpoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PASDAS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAP
Number of subjects: 0
Study: 38955966

Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 463

Group type: COMPARATOR
Intervention: MCV4-TT
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: MenACYW-TT/9vHPV/Tdap-IPV
Number of subjects: 463
Study: 38956196

Group type: EXPERIMENTAL
Intervention: Dasatinib plus quercetin (D + Q)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dasatinib plus quercetin (D + Q) in high senescent cell burden women
Number of subjects: 60
Study: 38956317

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) with PerioRisk information (RISK group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational interviewing (MI) without PerioRisk information (CTR group)
Number of subjects: 0
Study: 38956498

Group type: EXPERIMENTAL
Intervention: Team training programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ISBAR communication tool
Number of subjects: 0
Study: 38956510

Group type: EXPERIMENTAL
Intervention: Peer2Me intervention (mentorship by AYA survivor for 3 months)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Single AYA-specific consultation (control condition)
Number of subjects: 180
Study: 38956517

Group type: EXPERIMENTAL
Intervention: Unvaccinated participants
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Unvaccinated participants from Allada with at least one previous morbidity
Number of subjects: 861

Group type: COMPARATOR
Intervention: COVID-19 vaccination coverage
Number of subjects: 861
Study: 38956562

Group type: EXPERIMENTAL
Intervention: Instructional video followed by self-study (Vid-Self) in Study 1 (n=42)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Self-study followed by instructional video (Self-Vid) in Study 1 (n=36)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Self-Vid after seven days (Study 1)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Instructional video followed by self-study (Vid-Self) in Study 2 (n=30)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Self-study followed by instructional video (Self-Vid) in Study 2 (n=30)
Number of subjects: 138
Study: 38956594

Group type: EXPERIMENTAL
Intervention: 25 mg psilocybin
Number of subjects: 50

Group type: COMPARATOR
Intervention: 25 mg microcrystalline cellulose (MCC) placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Psilocybin and MCC placebo
Number of subjects: 50
Study: 38956609

Group type: EXPERIMENTAL
Intervention: Mail-order pharmacy dispensing for medication abortion
Number of subjects: 24
Study: 38956628

Group type: EXPERIMENTAL
Intervention: Psychosocial support delivered by traditional healers for 12 months
Number of subjects: 650

Group type: COMPARATOR
Intervention: Standard clinic-based HIV care alone
Number of subjects: 650
Study: 38956637

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention bundle
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study: 38956664

Group type: EXPERIMENTAL
Intervention: Esketamine combined with dexmedetomidine
Number of subjects: 134

Group type: COMPARATOR
Intervention: Dexmedetomidine alone
Number of subjects: 134
Study: 38956675

Group type: EXPERIMENTAL
Intervention: mHealth intervention group (Heart4U application)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 580
Study: 38956676

Group type: EXPERIMENTAL
Intervention: INtubate-RECruit-SURfactant-Extubate (IN-REC-SUR-E)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Less-invasive surfactant administration (LISA)
Number of subjects: 382
Study: 38956698

Group type: EXPERIMENTAL
Intervention: D3 lymph node dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: D2 lymph node dissection
Number of subjects: 0
Study: 38956809

Group type: EXPERIMENTAL
Intervention: Vincristine exposure with a 20% dose increase for low exposure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vincristine exposure without dose increase
Number of subjects: 15
Study: 38956881

Group type: COMPARATOR
Intervention: Supportive periodontal care with subgingival instrumentation (control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Supportive periodontal care without subgingival instrumentation (test)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (SPC with and without instrumentation)
Number of subjects: 62
Study: 38956935

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 0
Study: 38956940

Group type: EXPERIMENTAL
Intervention: FFR-guided strategy
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: IVUS-guided strategy
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 551

Group type: COMPARATOR
Intervention: Negative FFR
Number of subjects: 551

Group type: COMPARATOR
Intervention: Negative IVUS
Number of subjects: 551
Study: 38957011

Group type: EXPERIMENTAL
Intervention: Biopsy sampling during EGD
Number of subjects: 671
Study: 38957026

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38957149

Group type: EXPERIMENTAL
Intervention: PTSD and BPD symptoms
Number of subjects: 0
Study: 38957151

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 250
Study: 38957201

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 as an adjuvant therapy to letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letrozole alone (control)
Number of subjects: 0
Study: 38957349

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) with 3 sessions at 2000 impulses, 2.2 Bars pressure, 8 Hz frequency, with a 2-week interval between sessions (Experimental Group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) with 3 sessions at 2000 impulses, 2.2 Bars pressure, 8 Hz frequency, with a 4-week interval between sessions (Experimental Group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control Group receiving 3 rESWT sessions with a 1-week interval between each session
Number of subjects: 72
Study: 38957588

Group type: EXPERIMENTAL
Intervention: A2 milk
Number of subjects: 40

Group type: COMPARATOR
Intervention: A1/A2 milk
Number of subjects: 40
Study: 38957727

Group type: EXPERIMENTAL
Intervention: Late-life basic education
Number of subjects: 108
Study: 38957856

Group type: EXPERIMENTAL
Intervention: Mobile app-based mindfulness intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 56
Study: 38957926

Group type: EXPERIMENTAL
Intervention: Gyrolab for quantifying CB307
Number of subjects: 0
Study: 38958059

Group type: EXPERIMENTAL
Intervention: Study group (children with large overjet due to mandibular retrognathia)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (children with neutral occlusion)
Number of subjects: 37
Study: 38958149

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 9132
Study: 38958195

Group type: EXPERIMENTAL
Intervention: Triptorelin 11.25 mg at baseline (≤ 8 weeks after RP) and at 3 and 6 months
Number of subjects: 226

Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 226
Study: 38958479

Group type: EXPERIMENTAL
Intervention: Eltrombopag plus diacerein
Number of subjects: 102

Group type: COMPARATOR
Intervention: Eltrombopag monotherapy
Number of subjects: 102
Study: 38958732

Group type: EXPERIMENTAL
Intervention: Centanafadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylphenidate hydrochloride ER (Concerta)
Number of subjects: 0
Study: 38958839

Group type: EXPERIMENTAL
Intervention: Rapid eGFR decline
Number of subjects: 804237

Group type: EXPERIMENTAL
Intervention: Mean annual eGFR decline
Number of subjects: 804237
Study: 38958845

Group type: EXPERIMENTAL
Intervention: New line of therapy following osimertinib and PBC
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: New line of therapy following osimertinib and PBC (matched subset)
Number of subjects: 273
Study: 38958846

Group type: EXPERIMENTAL
Intervention: Niraparib plus abiraterone acetate and prednisone (AAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olaparib monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olaparib plus AAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Talazoparib plus enzalutamide
Number of subjects: 0
Study: 38958913

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 6355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6355

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 6355
Study: 38958978

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral self-help intervention (12 weekly modules)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Waiting-list control group (routine care only)
Number of subjects: 154
Study: 38958989

Group type: EXPERIMENTAL
Intervention: Lerodalcibep, 300 mg, subcutaneous injection, monthly for 52 weeks
Number of subjects: 922

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 922
Study: 38959017

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Very low-energy diet (VLED)
Number of subjects: 78
Study: 38959024

Group type: EXPERIMENTAL
Intervention: Self-guided 8-week web-based intervention
Number of subjects: 1607
Study: 38959264

Group type: EXPERIMENTAL
Intervention: Water service quality improvements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water quantity supplied
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water service continuity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased water supply by 5 L/user/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased water supply by 1.2 hours per day
Number of subjects: 0
Study: 38959294

Group type: EXPERIMENTAL
Intervention: Digitally-enabled community health worker (CHW) care (digital platform + CHW)
Number of subjects: 56

Group type: COMPARATOR
Intervention: CHW-enhanced usual care (CHW only)
Number of subjects: 56
Study: 38959480

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (2.0 mg/kg every 3 weeks)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice: topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice)
Number of subjects: 502
Study: 38959500

Group type: EXPERIMENTAL
Intervention: QCG-Critical score for critical events (AI-based ECG score)
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: QCG-Critical score (AI-based ECG score)
Number of subjects: 1254
Study: 38959589

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 149

Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 149
Study: 38959665

Group type: EXPERIMENTAL
Intervention: Higher Diet Quality Index (DQI)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Nutritional knowledge
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Ultra-processed foods
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Diet Quality Index (DQI)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Planetary Health Diet Index
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Higher DQI
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 236
Study: 38959779

Group type: EXPERIMENTAL
Intervention: Losmapimod (15 mg twice daily for 52 weeks)
Number of subjects: 14
Study: 38960001

Group type: EXPERIMENTAL
Intervention: STH≤2 mm (A-I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: STH>2 mm (B-I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Subcrestal placement (A-II, B-II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: STH>2 mm
Number of subjects: 80
Study: 38960044

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg plus ramipril for 4 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Hyperglycemia
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 79
Study: 38960463

Group type: EXPERIMENTAL
Intervention: Active MRI-guided rTMS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham MRI-guided rTMS
Number of subjects: 48
Study: 38960464

Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 307
Study: 38960465

Group type: EXPERIMENTAL
Intervention: Arm A: Rapid hepatitis C virus (HCV) antibody testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm B: Rapid HCV antibody and rapid RNA testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm C: Rapid HCV antibody testing and same-day treatment initiation for HCV antibody-positive participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm: Standard of care
Number of subjects: 0
Study: 38960495

Group type: EXPERIMENTAL
Intervention: Social network intervention (weekly social-health classroom interventions for 9 to 10 months)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 494
Study: 38960508

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 13970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13970
Study: 38960570

Group type: COMPARATOR
Intervention: Control group following Mediterranean diet recommendations
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Personalized Nutrition (PN)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Personalized Plan (PP)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Personalized recommendations (PN and PP)
Number of subjects: 193
Study: 38960586

Group type: EXPERIMENTAL
Intervention: Inclusion Body Myositis Functional Rating Scale (IBMFRS)
Number of subjects: 150
Study: 38960600

Group type: EXPERIMENTAL
Intervention: Collaborative ACP (col-ACP)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Supportive intervention (active control)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 277
Study: 38960626

Group type: EXPERIMENTAL
Intervention: Methylphenidate (30% symptom improvement at 2 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ADHD treatment responders
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ADHD nonresponders
Number of subjects: 60

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study: 38960798

Group type: EXPERIMENTAL
Intervention: durvalumab + olaparib
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: durvalumab + cediranib
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: durvalumab + olaparib and durvalumab + cediranib
Number of subjects: 50
Study: 38960812

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 19000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19000
Study: 38960832

Group type: EXPERIMENTAL
Intervention: ivabradine (2.5, 5.0, or 7.5 mg) administered twice daily from the morning of surgery until postoperative day 2.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo administered twice daily from the morning of surgery until postoperative day 2.
Number of subjects: 78
Study: 38960881

Group type: EXPERIMENTAL
Intervention: Robot-assisted oesophagectomy (RAO)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic oesophagectomy (VAO)
Number of subjects: 203
Study: 38960885

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Totally laparoscopic distal gastrectomy (TLDG)
Number of subjects: 442
Study: 38960907

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 48 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 14
Study: 38960969

Group type: EXPERIMENTAL
Intervention: D-dimer levels
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: MR-proADM levels
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Copeptin levels
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: ADL index
Number of subjects: 572
Study: 38961047

Group type: EXPERIMENTAL
Intervention: mAb treatment (casirivimab plus imdevimab 1200 mg)
Number of subjects: 2077
Study: 38961193

Group type: EXPERIMENTAL
Intervention: Nurse-led sexual rehabilitation intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 229
Study: 38961385

Group type: EXPERIMENTAL
Intervention: First mobilization out of bed within the first 24 hours after surgery
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: First mobilization within 6 hours after surgery
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Time to first mobilization after surgery
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Duration of first mobilization session
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Correlation between intubation time and first mobilization timing
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Correlation between timing of mobilization and duration of mobilization session
Number of subjects: 290
Study: 38961388

Group type: EXPERIMENTAL
Intervention: MiECC
Number of subjects: 60

Group type: COMPARATOR
Intervention: CECC
Number of subjects: 60
Study: 38961397

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study: 38961419

Group type: EXPERIMENTAL
Intervention: Combination of biomarkers including I-FABP, Alpha-GST, IL-6, PCT, IMA, D-lactate, D-dimer, SCUBE-1, LBP
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Biomarkers with at least moderate accuracy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Best models for each comparison
Number of subjects: 250
Study: 38961421

Group type: COMPARATOR
Intervention: Lifestyle-only group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle + medical food group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined intervention groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38961430

Group type: EXPERIMENTAL
Intervention: LVL UP App (holistic lifestyle intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oura ring (for tracking physical activity, sleep, and heart rate variability)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAPPY App (provides health promotion information)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holistic lifestyle mHealth intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health literacy and psychoeducational coaching sessions, daily 'Life Hacks', slow-paced breathing exercises, step tracker, low-burden food diary, journaling tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 0
Study: 38961439

Group type: EXPERIMENTAL
Intervention: Upfront cytoreductive nephrectomy (CN)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Deferred cytoreductive nephrectomy (CN)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Systemic therapy (ST) only with nivolumab plus ipilimumab
Number of subjects: 55
Study: 38961443

Group type: EXPERIMENTAL
Intervention: Hemoglobin transfusion thresholds
Number of subjects: 0
Study: 38961460

Group type: EXPERIMENTAL
Intervention: Multimodal therapeutic intervention with additional photobiomodulation therapy (PBMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stand-alone multimodal therapeutic intervention
Number of subjects: 0
Study: 38961462

Group type: EXPERIMENTAL
Intervention: Non-symbolic magnitude comparison task
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Working memory index
Number of subjects: 15
Study: 38961468

Group type: EXPERIMENTAL
Intervention: INTELLiVENT-adaptive support ventilation (ASV)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: INTELLiVENT-ASV
Number of subjects: 328
Study: 38961489

Group type: EXPERIMENTAL
Intervention: Intervention group (staff-led physical activity intervention)
Number of subjects: 819

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 819
Study: 38961496

Group type: EXPERIMENTAL
Intervention: Multidimensional and multiprofessional care assessment through a cross-sectional survey
Number of subjects: 500
Study: 38961501

Group type: EXPERIMENTAL
Intervention: Predictive machine-learning algorithm to prompt interpreter services
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care relying on clinician initiative to request interpreter services
Number of subjects: 35
Study: 38961532

Group type: EXPERIMENTAL
Intervention: Exercise ECG (positive results)
Number of subjects: 2457

Group type: EXPERIMENTAL
Intervention: Having at least two CVD risk factors
Number of subjects: 2457
Study: 38962217

Group type: EXPERIMENTAL
Intervention: Partnered dance
Number of subjects: 52

Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 52
Study: 38962436

Group type: EXPERIMENTAL
Intervention: GOE (900 mg/day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145